GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

suvemcitug   Click here for help

GtoPdb Ligand ID: 14397

Synonyms: BD-0801 | BD0801 | Enzeshu® (China)
Approved drug
suvemcitug is an approved drug
Compound class: Antibody
Comment: Suvemcitug (BD0801) is a humanized anti-VEGFA monoclonal antibody that was designed for anti-tumour action [1].
No information available.
Summary of Clinical Use Click here for help
First approval was granted by China's NMPA in 2025, to treat recurrent ovarian, fallopian tube, or primary peritoneal cancers in combination with paclitaxel, liposomal doxorubicin, or topotecan.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04908787 A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer Phase 3 Interventional Jiangsu Simcere Pharmaceutical Co., Ltd. 1